Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity
Open Access
- 15 August 2003
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (16), 8843-8856
- https://doi.org/10.1128/jvi.77.16.8843-8856.2003
Abstract
Vesicular stomatitis virus (VSV) is a negative-stranded RNA virus normally sensitive to the antiviral actions of alpha/beta interferon (IFN-α/β). Recently, we reported that VSV replicates to high levels in many transformed cells due, in part, to susceptible cells harboring defects in the IFN system. These observations were exploited to demonstrate that VSV can be used as a viral oncolytic agent to eradicate malignant cells in vivo while leaving normal tissue relatively unaffected. To attempt to improve the specificity and efficacy of this system as a potential tool in gene therapy and against malignant disease, we have genetically engineered VSV that expresses the murine IFN-β gene. The resultant virus (VSV-IFNβ) was successfully propagated in cells not receptive to murine IFN-α/β and expressed high levels of functional heterologous IFN-β. In normal murine embryonic fibroblasts (MEFs), the growth of VSV-IFNβ was greatly reduced and diminished cytopathic effect was observed due to the production of recombinant IFN-β, which by functioning in a manner involving autocrine and paracrine mechanisms induced an antiviral effect, preventing virus growth. However, VSV-IFNβ grew to high levels and induced the rapid apoptosis of transformed cells due to defective IFN pathways being prevalent and thus unable to initiate proficient IFN-mediated host defense. Importantly, VSV expressing the human IFN-β gene (VSV-hIFNβ) behaved comparably and, while nonlytic to normal human cells, readily killed their malignant counterparts. Similar to our in vitro observations, following intravenous and intranasal inoculation in mice, recombinant VSV (rVSV)-IFNβ was also significantly attenuated compared to wild-type VSV or rVSV expressing green fluorescent protein. However, VSV-IFNβ retained propitious oncolytic activity against metastatic lung disease in immunocompetent animals and was able to generate robust antitumor T-cell responses. Our data indicate that rVSV designed to exploit defects in mechanisms of host defense can provide the basis for new generations of effective, specific, and safer viral vectors for the treatment of malignant and other disease.Keywords
This publication has 62 references indexed in Scilit:
- Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant DiseaseJournal of Virology, 2002
- Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV ChallengeJournal of Virology, 2001
- Induction of a TRAIL mediated suicide program by interferon alpha in primary effusion lymphomaOncogene, 2001
- Adenovirus-mediated interferon-β gene therapy suppresses growth and metastasis of human prostate cancer in nude miceCancer Gene Therapy, 2001
- Host defense, viruses and apoptosisCell Death & Differentiation, 2001
- Inhibition of Angiogenesis and Vascular Tumor Growth by Interferon-Producing Cells: A Gene Therapy ApproachThe American Journal of Pathology, 2000
- Recent Developments in the Virus Therapy of CancerProceedings of the Society for Experimental Biology and Medicine, 2000
- Functional Role of Type I and Type II Interferons in Antiviral DefenseScience, 1994
- Targeted mutation of the DNA methyltransferase gene results in embryonic lethalityCell, 1992
- Differing responses of hamsters to infection by vesicular stomatitis virus Indiana and New Jersey serotypesVirus Research, 1985